Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
For the first time, a major randomized trial confirms that statins benefit healthy older adults. The STAREE trial found that daily atorvastatin 40 mg significantly reduced the risk of major cardiovascular events — including heart attacks and strokes — in people aged 70 and older compared to placebo. Researchers are now calling for updated treatment guidelines to reflect this landmark finding.
For decades, the question of whether statins are worth it for healthy older adults with no prior heart disease has been hotly debated. Now, the STAREE trial — the largest randomized study of its kind — has delivered a clear answer: yes, at least for cardiovascular protection. Daily atorvastatin 40 mg reduced the composite risk of cardiovascular death, nonfatal heart attack or stroke, and coronary revascularization by 30% compared to placebo over nearly six years in nearly 10,000 adults aged 70 and older.
The benefits were consistent across age groups, LDL levels, blood pressure, BMI, and kidney function — and held up despite real-world challenges like dropouts and dose changes. That said, statins didn't move the needle on disability-free survival (combining death from any cause, dementia, or persistent physical disability), leaving some nuance for clinicians to weigh.
By the Numbers:
Why it matters: These results could reshape prescribing guidelines for older adults, a population previously given only a weak recommendation for statins. Researchers are urging guideline bodies to act — and are calling for more studies on higher doses and combination therapies.
